Researchers in Brazil Enhance Cancer Immunotherapy with Engineered Natural Killer Cells

Scientists at the Ribeirão Preto Blood Center and the Center for Cell-Based Therapy (CTC) in Brazil have developed a novel approach to cancer immunotherapy by optimizing natural killer (NK) cells with enhanced chimeric antigen receptors (CARs), according to a study published in *Frontiers in Immunology*. The research, supported by FAPESP, demonstrates that incorporating specific signaling domains into CAR-NK cells improves their ability to target and destroy tumor cells, offering a potential advance in cancer treatment.

How Do CAR-NK Cells Work?

CAR-based therapies, such as CAR-T cell treatments, have revolutionized cancer care, particularly for blood cancers. However, CAR-NK cells—derived from NK cells—remain less studied. The Brazilian team focused on the NK-92 cell line, engineering CARs with costimulatory components like 2B4 and DAP12. These additions “made the cells ready to attack,” significantly boosting their tumor-killing capacity.

What Makes This Research Unique?

The study addresses a critical challenge in CAR-NK therapy: identifying signaling mechanisms that maximize cell activity. By integrating 2B4 and DAP12, the researchers enhanced the activation state of NK cells, making them more effective against tumors. The team also tested a drug-based control system using dasatinib to temporarily suppress cell activity. Results suggested that combining optimized activation signals with pharmacological control could improve the precision and efficiency of CAR-NK treatments.

What Were the Results in Preclinical Models?

Experiments in animal models showed that CAR-NK cells with 2B4-DAP12 and dasatinib pretreatment outperformed traditional therapies in controlling tumor growth. The findings, detailed in the *Frontiers in Immunology* study, highlight the potential for more adaptable and potent cell-based cancer treatments.

Why Does This Matter for Cancer Treatment?

The Brazilian study’s focus on signaling domains and drug modulation provides a framework for refining CAR-NK therapies.

What’s Next for This Research?

Meanwhile, the research underscores the growing role of cell-based immunotherapies in oncology, with institutions like the CTC playing a key part in driving innovation.

For more details, refer to the original study in Frontiers in Immunology and updates from the FAPESP.